UNSPSC 51142316: Naloxone hydrochloride dihydrate

This classification denotes an opiate antagonist with the molecular formula C19H21NO4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Q187997EE, chemically known as (-)-n-allyl-14-hydroxynordihydromorphinone hydrochloride dihydrate, but more generally known as naloxone hydrochloride dihydrate, which bears US NIH Compound Identifier 5464092. European Medicines Agency schedules naloxone hydrochloride dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09142MIG.

Most nations, for tariff purposes, schedule naloxone hydrochloride dihydrate under HS 29391900. SMILES: C=CCN1CC[C@]23C4C5CCC(C4O[C@H]2C(=O)CC[C@]3([C@H]1C5)O)O.O.O.CL.

UNSPSC 51142316 Naloxone hydrochloride dihydrate is a Commodity code representing pharmaceutical products that state and local governments procure to support emergency health response, community health initiatives, and pharmacy benefit programs. The scope of work includes supply of naloxone units for emergency responders and community health settings, as well as participation in broader pharmaceutical sourcing programs that bundle naloxone with generic multi-source drugs and over-the-counter products for distribution across state and local facilities. Issuing bodies span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida and the Texas Health and Human Services Commission represent the active buyer mix, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering contracts serving state and local government participants across multiple states including Oregon.

Recent activity centers on three procurement types with different strategic purposes. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, signaling early-stage market exploration before formal procurement. MMCAP issued an RFP in January 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awarded vendors effective July 1, 2026. Geographic activity is concentrated in Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative structure extending into Oregon and other participating jurisdictions.